

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) Antibiotic coated porous bodies consisting essentially of ~~comprising~~ a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group consisting of the netilmicin laurate, the netilmicin dodecyl sulfate, the netilmicin myristate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the vancomycin laurate, the vancomycin dodecyl sulfate, the vancomycin myristate, the vancomycin teicoplanin, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin laurate, the ciprofloxacin myristate and the clindamycin teicoplanin, said coating being introduced onto an inner surface into a porous system-of non-metallic porous bodies and/or of metallic porous bodies.

2. (Currently amended) Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising introducing first an aqueous solution, containing at least one representative of an easily water soluble salt of at least one of netilmicin, sisomicin, clindamycin, amikacin, kanamycin, tobramycin, vancomycin, and ciprofloxacin, onto an inner surface of porous bodies, and that after a drying phase, introducing a second aqueous solution of an easily water soluble salt of lauric acid, myristic acid and/or dodecyl sulphuric acid and thereby developing a hardly water soluble antibiotic

coating on an inner surface in the porous system of the porous body.

3. (Original) Method pursuant to claim 2, wherein the sequence of the introducing steps is reversed.

4. (Previously amended) Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising introducing a methanolic solution or an ethanolic solution of at least one representative from the group consisting of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin onto an inner surface into the porous system of porous bodies and vaporizing or evaporating methanol or ethanol to form a hardly water soluble antibiotic coating.

5. (Previously amended) Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising partially dissolving and/or suspending in a dioxane-water and/or in a tetrahydrofurane-water mixture amikacin laurate, kanamycin laurate, amikacin dodecyl sulfate and/or kanamycin dodecyl sulfate to form solutions and/or suspensions and introducing these solutions and/or suspensions onto an inner surface into the porous system of the porous bodies and vaporizing or evaporating the dioxane and water mixtures or the tetrahydrofurane and water mixtures to form an antibiotic coating that is hardly soluble in water.

6. (Original) Antibiotic coated porous bodies pursuant to claim 1, wherein the antibiotic coating is applied to porous bodies existing in the form of porous powders, porous granules, porous molded

bodies and/or porous layers on compact bodies.

7. (Previously amended) Antibiotic coated porous bodies pursuant to claim 1, wherein the coating for porous bodies, which optionally exists in the form of porous powders and/or porous granules, is produced through a grinding process by the addition of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group consisting of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the ciprofloxacin myristate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin dodecyl sulfate, the vancomycin teicoplanin and the clindamycin teicoplanin, in the presence of methanol, ethanol, dioxane, tetrahydrofuran and/or water or mixtures thereof.

8. (Previously amended) Antibiotic coated porous bodies pursuant to claim 1, wherein the coating for porous bodies, which optionally exists in the form of porous powders and/or porous granules, is produced through a grinding process by the addition of a mixture of at least one water soluble salt of netilmicin, sisomicin, clindamycin, amikacin, kanamycin, tobramycin, vancomycin and/or ciprofloxacin and at least one water soluble salt of lauric acid, myristic acid and/or dodecyl sulphuric acid in the presence of water or aqueous solutions.

9. (Original) Antibiotic coated porous bodies pursuant to claim 1, wherein the coating additionally

contains easily water soluble salts of gentamicin, netilmicin, sisomicin, amikacin, kanamycin, clindamycin, tobramycin, vancomycin, ciprofloxacin and/or moxifloxacin.

10. (Original) Antibiotic coated porous bodies pursuant to claim 1, wherein the antibiotic coating is applied to resorbable porous bodies, to partially resorbable porous bodies and/or to non-resorbable, bio-compatible porous bodies.

11. (Original) Implants comprising antibiotic coated porous bodies pursuant to claim 1, which have been pressed into molded bodies with a shape of coated porous granules and/or coated porous powders.

12. (Original) Binding agents for the production of molded bodies through a pressing operation of powder mixtures, comprising antibiotic coated porous bodies pursuant to claim

1, which have been designed as antibiotically coated porous granules and/or antibiotically coated porous powders.

13. (Original) Temporary or permanent implants comprising antibiotic coated porous bodies pursuant to claim 1.

14. (Original) Antibiotic coated porous bodies pursuant to claim 1, with hardly water soluble salts from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate,

the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin dodecyl sulfate, the ciprofloxacin laurate, the ciprofloxacin myristate and/or the clindamycin laurate.

15. (Previously amended) Implants comprising antibiotic coated porous bodies pursuant to claim

14.